Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target

Leukemia. 2023 Dec;37(12):2507-2511. doi: 10.1038/s41375-023-02044-2. Epub 2023 Nov 2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use
  • Humans
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / genetics
  • Prognosis

Substances

  • Azacitidine